Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe symbols : Hznp save search
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
Published: 2023-10-02 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.1%
H: 0.13%
C: 0.11%
uplizna therapeutics
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
Published: 2023-09-29 (Crawled : 23:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: -0.05%
tepezza disease treatment thyroid eye
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
Published: 2023-08-23 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.2%
H: 1.37%
C: 1.01%
rare disease therapeutics
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
Published: 2023-07-17 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 0.32%
C: -0.19%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.25%
H: 0.76%
C: 0.43%
therapeutics financial results
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
Published: 2023-07-06 (Crawled : 15:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: -0.29%
krystexxa trial injection
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.43%
H: 0.48%
C: 0.38%
tepezza disease active approved treatment thyroid brazil eye
UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2023-06-12 (Crawled : 16:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.15%
uplizna biomarker publication trial
New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
Published: 2023-05-31 (Crawled : 17:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.1%
H: 1.32%
C: 0.58%
trial
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
Published: 2023-05-31 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.1%
H: 1.32%
C: 0.58%
trial results
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
Published: 2023-05-09 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.13%
H: 0.61%
C: 0.15%
therapeutics
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
Published: 2023-05-03 (Crawled : 12:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.86%
H: 0.63%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.0%
H: 0.14%
C: -2.82%
therapeutics financial results
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Published: 2023-05-02 (Crawled : 16:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 0.04%
C: -0.21%
lupus treatment trial therapeutics phase 2
Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023
Published: 2023-04-14 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.25%
H: 1.1%
C: 0.54%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.33%
H: 0.45%
C: -0.25%
therapeutics financial results
Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.0%
H: 0.47%
C: -0.32%
global grant program therapeutics
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2022-12-20 (Crawled : 15:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.03%
H: 0.21%
C: 0.03%
uplizna treatment brazil approved
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
Published: 2022-11-08 (Crawled : 19:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.17%
H: 1.35%
C: -0.89%
krystexxa trial response injection
Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
Published: 2022-10-13 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -2.16%
H: 6.54%
C: 5.48%
tepezza thyroid disease meeting eye therapeutics
Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
Published: 2022-10-06 (Crawled : 19:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.82%
H: 2.83%
C: 2.09%
therapeutics financial results
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
Published: 2022-09-12 (Crawled : 13:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 1.57%
H: 1.42%
C: -0.67%
treatment trial therapeutics phase 2
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
Published: 2022-08-03 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -21.9%
H: 5.69%
C: 4.4%
sales therapeutics results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.